Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Passing the Torch forward: Moving beyond EGFR Inhibition in NMIBC Prevention.

Cancer prevention research (Philadelphia, Pa.) - 6 Jan 2025

Wu Tsung-Che, Lin Chia-Chi

Abstract excerpt

The study by Downs and colleagues targets patients with non-muscle-invasive bladder cancer (NMIBC) to explore secondary/tertiary cancer prevention strategies. Utilizing a "window-of-opportunity" design, erlotinib was evaluated for its effect on EGFR phosphorylation, although the unconventional dosing regimen failed to demonstrate efficacy. New opportunities in NMIBC prevention include targeting FGFR3 mutations...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ErbB Receptors
Share to Erlotinib Hydrochloride
Share to FGFR3 gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Neoplasm Recurrence, Local

Share to Protein Kinase Inhibitors

Share to Receptor, Fibroblast Growth Factor, Type 3

Share to Urinary Bladder Neoplasms

Source

Identifiers

PMID: 39757805
DOI: 10.1158/1940-6207.CAPR-24-0491

Genes

EGFR
FGFR3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Passing the Torch forward: Moving beyond EGFR Inhibition in NMIBC Prevention.PMID 39757805Read ↗

A place for precision medicine in bladder cancer: targeting the FGFRs.Semantic proximity Read ↗

FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies.Semantic proximity Read ↗

New and promising strategies in the management of bladder cancer.Semantic proximity Read ↗

Role of FGFR3 in bladder cancer: Treatment landscape and future challenges.Semantic proximity Read ↗

Emerging therapeutic targets in bladder cancer.Semantic proximity Read ↗

Guidance of adjuvant instillation in intermediate risk non- muscle invasive bladder cancer by drug screens in patient derived organoids. A Single center, Open-label, Phase II trial. GAIN-INST-TrialSemantic proximity Read ↗

FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.Semantic proximity Read ↗

FGFR Inhibitors in Urothelial Cancer: From Scientific Rationale to Clinical Development.Semantic proximity Read ↗

MET signaling drives acquired resistance to erdafitinib in muscle-invasive bladder cancer cellsSemantic proximity Read ↗

Biomarker-Oriented Therapy in Bladder and Renal Cancer.Semantic proximity Read ↗

FGFR3 – a Central Player in Bladder Cancer Pathogenesis?Semantic proximity Read ↗

A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.